PharmaShots | Incisive News in 3 Shots

Subscribe Now

1EP & 2EP

Regeneron's Eylea (aflibercept) Achieves 1EP & 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

Regeneron's Eylea (aflibercept) Achieves 1EP & 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinop...

October 26, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us